Certara Announces CFO Transition
RADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader…
CertaraJune 17, 2026
Migrating to Chemaxon Java Libraries 26: What Changed and How to Adapt
Chemaxon Java Libraries 26 moves to Java 21 with a reorganized API—relocated classes and renamed…
CertaraJune 17, 2026
Precursor chemicals – Sine qua non
Learn about precursor chemicals, and which drug precursors are controlled in the European Union as…
CertaraJune 16, 2026
Mechanistic QSP Modeling to Support KIT Inhibitor Dose Selection, Biomarker Strategy, and Clinical Development
Discover how a mechanistic quantitative systems pharmacology (QSP) model predicts mast cell inhibition and depletion…
CertaraJune 16, 2026
Building IND-Ready and Investor-Ready Development Programs
Learn how emerging biotechs can build IND-ready, investor-ready development programs using Totality of Evidence, NAMs,…
CertaraJune 15, 2026
Data, models, and modalities: Key themes from the Certainty 2026 Discovery UGM
A recap of the Certainty 2026 Discovery UGM in Boston, covering the top themes from…
CertaraJune 15, 2026
Certara Integrates D360™ with Secondary Intelligence™ Software to Enhance Predicting Drug Safety Risk
Certara integrates D360 with Secondary Intelligence to help drug researchers identify off-target safety risks earlier…
CertaraJune 12, 2026
Certara Reappointed for a European Medicines Agency Contract, Expanding Opportunities to Shape the Future of Real-World Evidence for Regulatory Decision-Making
Certara was reappointed to a 4 year EMA and ECDC framework contract to generate real-world…
CertaraJune 11, 2026
2026 Simcyp Workshops
Advance your PBPK and model-informed drug development expertise with Simcyp workshops. Learn from experts through…
CertaraJune 11, 2026
QSP modeling for Parkinson’s disease: Solving the synthetic control challenge in clinical trials
QSP modeling for Parkinson’s disease tackles optimized standard-of-care, placebo response, and missing biomarkers. See how…
CertaraJune 11, 2026
